Less than a month after Merck notched an early OK to market a Keytruda combo as frontline therapy for renal cell carcinoma, rivals Pfizer and Merck KGaA have arrived at the scene with its own FDA approval.
As is the case with Keytruda, their PD-L1 inhibitor Bavencio is sanctioned for use with Inlyta, a tyrosine kinase inhibitor from Pfizer. In the Phase III JAVELIN Renal 101 study, this combo demonstrated a significant progression-free survival benefit: five months across the intent-to-treat patient population compared to the comparator arm, who were given Sutent. That surpassed the expectations of investigators as they initially narrowed the focus to PD-L1 positive patients.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.Free Subscription